The Current Ratio as of September 2024 (TTM) for Incyte Corporation (INCY) is 1.92

According to Incyte Corporation’s latest financial reports and current stock price. The company's current Current Ratio is 1.92. This represents a change of -40.64% compared to the average of 3.23 of the last 4 quarters.

Incyte Corporation (INCY) Historical Current Ratio (quarterly & annually)

How has INCY Current Ratio performed in the past?

The mean historical Current Ratio of Incyte Corporation over the last ten years is 3.32. The current 1.92 Current Ratio has changed 5.68% with respect to the historical average. Over the past ten years (40 quarters), INCY's Current Ratio was at its highest in in the June 2019 quarter at 5.61. The Current Ratio was at its lowest in in the December 2016 quarter at 0.82.

Incyte Corporation (INCY) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Incyte Corporation Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Incyte Corporation (INCY) Average Current Ratio

How has INCY Current Ratio performed in the past?

The current Current Ratio of Incyte Corporation (INCY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Incyte Corporation (INCY) Current Ratio vs. Peers

How is INCY’s Current Ratio compared to its peers?

Incyte Corporation’s Current Ratio is less than Alnylam Pharmaceuticals, Inc. (3.01), less than United Therapeutics Corporation (4.35), less than Ultragenyx Pharmaceutical Inc. (3.54), less than Apellis Pharmaceuticals, Inc. (5.08), less than BeiGene, Ltd. (1.98), less than BioMarin Pharmaceutical Inc. (3.05), less than ImmunoGen, Inc. (5.47), less than Prometheus Biosciences, Inc. (37.56), less than Arrowhead Pharmaceuticals, Inc. (4.65), less than Ionis Pharmaceuticals, Inc. (7.61), less than Axsome Therapeutics, Inc. (2.48), less than Sarepta Therapeutics, Inc. (3.90), less than ACADIA Pharmaceuticals Inc. (2.16), less than Amicus Therapeutics, Inc. (2.75), less than Denali Therapeutics Inc. (12.46), less than argenx SE (8.53), less than Harmony Biosciences Holdings, Inc. (3.13),

Build a custom stock screener for Incyte Corporation (INCY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Incyte Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Incyte Corporation (INCY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Incyte Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.